NCT01811498View on ClinicalTrials.gov

Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

August 31, 2021

Study Completion Date

October 31, 2021

Conditions
Glioblastoma MultiformeBrain Tumor
Interventions
DRUG

Bevacizumab

Trial Locations (1)

10065

Lenox Hill Brain Tumor Center, New York

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
collaborator

Feinstein Institute for Medical Research

OTHER

lead

Northwell Health

OTHER